BackNRX Pharmaceuticals- Warrants (24/05/2026) Overview

NRX Pharmaceuticals- Warrants (24/05/2026) Total Assets

Track NRX Pharmaceuticals- Warrants (24/05/2026)'s total assets ($12M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$11.90M
56.82% YoYΔ $4.31M vs prior year quarter

Peer average / median

Loading

NRX Pharmaceuticals- Warrants (24/05/2026) Total Assets History

Loading

NRX Pharmaceuticals- Warrants (24/05/2026) vs. peers: Total Assets Comparison

Loading

NRX Pharmaceuticals- Warrants (24/05/2026) Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NRX Pharmaceuticals- Warrants (24/05/2026) (NRXPW) FAQ

NRX Pharmaceuticals- Warrants (24/05/2026)'s total assets stands at $12M as of March 2026. That compares with $7.6M in the prior-year period — up 56.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

NRX Pharmaceuticals- Warrants (24/05/2026) reported $12M in total assets versus $7.6M a year earlier — a 56.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $7.6M in the prior-year period — up 56.8% year over year. Sustained growth in total assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how NRX Pharmaceuticals- Warrants (24/05/2026)'s total assets evolved across reporting periods, while the comparison chart places NRXPW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total assets is commonly used to spot outliers. NRX Pharmaceuticals- Warrants (24/05/2026)'s reading of $12M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.